ClinicalTrials.gg
CompletedNCT03176771Updated Jan 7, 2026Results posted

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

A Phase 2/3 interventional study of MT-5199 and Placebo in Tardive Dyskinesia, sponsored by Tanabe Pharma Corporation. Completed at 82 sites in Japan. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-01-07.

Sponsored by Tanabe Pharma Corporation · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
256
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.

Enrollment
Largest of 14
256 · median 101
Started
2017
the only one that year
Phase 2/3
Only one
of the 14
Registered
8th of 14
by date
Lead sponsor
1 of 14
Tanabe Pharma Corporation

Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one has the largest enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 8th registered.

Tardive Dyskinesia

62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.

Browse Tardive Dyskinesia studies →

Open to participants now

1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About valbenazine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing valbenazine in Tardive Dyskinesia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

03

Conditions studied

  • Tardive Dyskinesia

Browse trials for

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have one of the following clinical diagnoses for at least 3 months prior to screening: Schizophrenia or Schizoaffective Disorder, Bipolar Disorder, or Depressive Disorders.
  • Have a clinical diagnosis of neuroleptic-induced TD.
  • Have moderate or severe TD.
  • If using maintenance medication(s) for schizophrenia or schizoaffective disorder, or bipolar disorder, or depressive disorders, be on stable doses.

Exclusion criteria

Exclusion Criteria:

  • Have an active, unstable medical condition in screening period.
  • Have a significant risk of suicidal or violent behavior.
  • Have a known history of long syndrome or cardiac tachy-arrhythmia.
  • Are currently pregnant or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
256 participants (actual)

Study arms

  • Experimental
    MT-5199 40 mg (Double-Blind Placebo-Controlled Period)

    MT-5199 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning for 6 weeks.

    Drug: MT-5199 · Drug: Placebo

  • Experimental
    MT-5199 80 mg (Double-Blind Placebo-Controlled Period)

    Subjects randomized to the MT-5199 80 mg dose will receive MT-5199 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by MT-5199 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning for 5 weeks.

    Drug: MT-5199 · Drug: Placebo

  • Experimental
    Placebo (Double-Blind Placebo-Controlled Period)

    Placebo administered as two (2) placebo capsules, taken by mouth, every morning for 6 weeks.

    Drug: Placebo

  • Experimental
    MT-5199 40 mg (Double-Blind Extension Period)

    At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose.

    Drug: MT-5199 · Drug: Placebo

  • Experimental
    MT-5199 80 mg (Double-Blind Extension Period)

    At the end of Week 6, subjects will enter a double-blind extension period for 42 weeks. Subjects who were initially randomized to placebo will be re-randomized (1:1) to receive either MT-5199 40 mg or 80 mg and subjects initially randomized to MT-5199 will continue with their current dose. Subjects re-randomized to receive MT-5199 80 mg will receive 40 mg for the first week.

    Drug: MT-5199 · Drug: Placebo

Interventions

  • MT-5199 40 mg capsules

  • DrugPlacebo

    MT-5199 placebo capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6

    Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Baseline and Week 6

Secondary outcomes

  1. Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)

    Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)

    Time frame: Week 6

  2. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6

    Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

    Time frame: Baseline and Week 6

  3. Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6

    Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

    Time frame: Week 6

07

Results

Posted Aug 14, 2023

Participant flow

This study enrolled schizophrenia/schizoaffective disorder subject with tardive dyskinesia (TD), or bipolar disorder/depressive disorder with TD from 100 centers in Japan.The last patient completed in September 2020.

Double-Blind Placebo-Controlled Period
Participant flow — Double-Blind Placebo-Controlled Period
MilestonePlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Extension Period)MT-5199 80 mg (Double-Blind Extension Period)
Started85868500
Completed80716000
Not completed5152500
Withdrew: Adverse event351400
Withdrew: Physician decision02000
Withdrew: Withdrawal by subject281000
Withdrew: Incorrect allocation00100
Double-Blind Extension Period
Participant flow — Double-Blind Extension Period
MilestonePlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Extension Period)MT-5199 80 mg (Double-Blind Extension Period)
Started00011299
Completed0006750
Not completed0004549
Withdrew: Adverse event0001518
Withdrew: Death00034
Withdrew: Physician decision00031
Withdrew: Withdrawal by subject0002426

Outcome measures

PrimaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6

Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6
units on a scalePlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6-0.1 (-0.8 to 0.5)-2.3 (-3.0 to -1.7)-3.7 (-4.4 to -3.0)
Statistical analysis
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 80 mg (Double-Blind Placebo-Controlled Period) · Mixed-effect Model Repeated Measures · p = <0.001 · Mean difference (final values): -3.6 · 95% CI -4.5 to -2.6
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 40 mg (Double-Blind Placebo-Controlled Period) · Mixed-effect Model Repeated Measures · p = <0.001 · Median difference (final values): -2.2 · 95% CI -3.0 to -1.3
SecondaryPercentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)

Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)

Time frame:
Week 6
Reported as:
Number · percentage of AIMS responders
Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)
percentage of AIMS respondersPlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)
Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)10.323.947.2
Statistical analysis
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 40 mg (Double-Blind Placebo-Controlled Period) · Cochran-Mantel-Haenszel · p = 0.027 · Risk difference (rd): 13.6
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 80 mg (Double-Blind Placebo-Controlled Period) · Cochran-Mantel-Haenszel · p = <0.001 · Risk difference (rd): 36.9
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6

Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.

Time frame:
Baseline and Week 6
Reported as:
Least squares mean · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6
units on a scalePlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6-2.3 (-3.2 to -1.5)-3.8 (-4.7 to -3.0)-4.7 (-5.6 to -3.8)
Statistical analysis
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 40 mg (Double-Blind Placebo-Controlled Period) · Mixed-effect Model Repeated Measures · p = 0.013 · Mean difference (final values): -1.5 · 95% CI -2.7 to -0.3
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 80 mg (Double-Blind Placebo-Controlled Period) · Mixed-effect Model Repeated Measures · p = <0.001 · Mean difference (final values): -2.3 · 95% CI -3.5 to -1.1
SecondaryClinical Global Impression of Change - TD (CGI-TD) Score at Week 6

Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).

Time frame:
Week 6
Reported as:
Least squares mean · units on a scale
Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6
units on a scalePlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)
Clinical Global Impression of Change - TD (CGI-TD) Score at Week 63.4 (3.2 to 3.6)3.0 (2.8 to 3.3)2.8 (2.5 to 3.0)
Statistical analysis
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 40 mg (Double-Blind Placebo-Controlled Period) · ANOVA · p = 0.021 · Mean difference (final values): -0.4 · 95% CI -0.7 to -0.1
  • Placebo (Double-Blind Placebo-Controlled Period) vs MT-5199 80 mg (Double-Blind Placebo-Controlled Period) · ANOVA · p = <0.001 · Mean difference (final values): -0.6 · 95% CI -1.0 to -0.3

Adverse events

Collected over Up to Week 6 (Placebo, MT-5199 40 mg, MT-5199 80 mg), and Post Week 6 to Week 48 (MT-5199 40 mg, MT-5199 80 mg). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Double-Blind Placebo-Controlled Period)0/84 (0%)1/84 (1.2%)15/84 (17.9%)
MT-5199 40 mg (Double-Blind Placebo-Controlled Period)0/85 (0%)4/85 (4.7%)30/85 (35.3%)
MT-5199 80 mg (Double-Blind Placebo-Controlled Period)0/84 (0%)1/84 (1.2%)44/84 (52.4%)
MT-5199 40 mg (Double-Blind Extension Period)3/108 (2.8%)15/108 (13.9%)71/108 (65.7%)
MT-5199 80 mg (Double-Blind Extension Period)4/95 (4.2%)15/95 (15.8%)69/95 (72.6%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Extension Period)MT-5199 80 mg (Double-Blind Extension Period)
SchizophreniaPsychiatric disorders0/841/850/845/1081/95
DepressionPsychiatric disorders0/840/850/840/1082/95
DehydrationMetabolism and nutrition disorders0/840/851/840/1080/95
Suicide attemptPsychiatric disorders1/840/850/841/1080/95
Head injuryInjury, poisoning and procedural complications0/841/850/840/1080/95
Panic attackPsychiatric disorders0/841/850/840/1080/95
Suicidal ideationPsychiatric disorders0/841/850/840/1080/95
DeathGeneral disorders0/840/850/841/1081/95
PneumoniaInfections and infestations0/840/850/840/1081/95
Pneumonia bacterialInfections and infestations0/840/850/840/1081/95
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlacebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Extension Period)MT-5199 80 mg (Double-Blind Extension Period)
NasopharyngitisInfections and infestations6/846/854/8427/10820/95
SomnolenceNervous system disorders2/8410/8521/849/1088/95
SchizophreniaPsychiatric disorders1/847/850/8413/10813/95
Salivary hypersecretionGastrointestinal disorders1/843/859/847/10812/95
TremorNervous system disorders0/840/855/845/10811/95
InsomniaPsychiatric disorders1/842/855/848/10811/95
ConstipationGastrointestinal disorders1/842/851/847/1088/95
AkathisiaNervous system disorders1/844/855/844/1087/95
DepressionPsychiatric disorders1/841/853/845/1087/95
MalaiseGeneral disorders0/845/854/845/1086/95

Baseline characteristics

Safety analysis set

Age, Continuous
Age, Continuous(years)Placebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)Total
Mean60.0 ± 13.458.6 ± 14.058.0 ± 13.858.9 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)Total
Female484533126
Male364051127
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)Total
Hispanic or Latino0000
Not Hispanic or Latino848584253
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo (Double-Blind Placebo-Controlled Period)MT-5199 40 mg (Double-Blind Placebo-Controlled Period)MT-5199 80 mg (Double-Blind Placebo-Controlled Period)Total
Japanese848584253
Non-Japanese0000
08

Study locations

82 sites
  • Aichi Psychiatric Medical Center
    Aichi, Japan
  • Hotei Hospital
    Aichi, Japan
  • Mikawa Hospital
    Aichi, Japan
  • Okehazama Hospital Fujita Kokoro Care Center
    Aichi, Japan
  • Akita City Hospital
    Akita, Japan
  • Akita University Hospital
    Akita, Japan
  • Hirosaki Aiseikai Hospital
    Aomori, Japan
  • Minato Hospital
    Aomori, Japan
  • Seinan Hospital
    Aomori, Japan
  • Kohnodai Hospital , National Center for Global Health and Medicine
    Chiba, Japan
  • National Hospital Organization Shimofusa Psychiatric Medical Center
    Chiba, Japan
  • General incorporated association Shinkoukai Shinkouen
    Ehime, Japan
  • Chikusuikai Hospital
    Fukuoka, Japan
  • Fukuoka University Hospital
    Fukuoka, Japan
  • Hirota Clinic
    Fukuoka, Japan
  • Iizukakinen Hospital
    Fukuoka, Japan
  • Kuramitsu Hospital
    Fukuoka, Japan
  • Minamigaoka Hospital
    Fukuoka, Japan
  • Yahata Kousei Hospital
    Fukuoka, Japan
  • Nanko Kokorono Clinic
    Fukushima, Japan
  • Takeda General Hospital
    Fukushima, Japan
  • Holy Cross Hospital
    Gifu, Japan
  • Seimou Hospital
    Gunma, Japan
  • Hayakawa Clinic
    Hiroshima, Japan
  • Kamo Psychiatric Center
    Hiroshima, Japan
  • Medical corporation KOSEIKAI KUSATSU HOSPITAL
    Hiroshima, Japan
  • Mihara Hospital
    Hiroshima, Japan
  • Hayashishita Hospital
    Hokkaido, Japan
  • Ishikane Hospital
    Hokkaido, Japan
  • National Hospital Organization Hokkaido Medical Center
    Hokkaido, Japan
  • Obihiro-Kosei General Hospital
    Hokkaido, Japan
  • Sapporo City General Hospital
    Hokkaido, Japan
  • Teine Hospital
    Hokkaido, Japan
  • Hyogo prefecture - Hyogo Mental Health Center
    Hyōgo, Japan
  • Kobe University Hospital
    Hyōgo, Japan
  • Medical corporation Shouhokai Toda Internal Medicine and Rehabilitation Department
    Hyōgo, Japan
  • Awazu Neuropsychiatric Sanatorium
    Ishikawa, Japan
  • Ishiki Hospital
    Kagoshima, Japan
  • Minami Kyushu Sakura Hospital
    Kagoshima, Japan
  • Taniyama Hospital
    Kagoshima, Japan
  • Fujimidai Hospital
    Kanagawa, Japan
  • Hatano Kosei Hospital
    Kanagawa, Japan
  • Hino Hospital
    Kanagawa, Japan
  • Kishiro Mental Clinic
    Kanagawa, Japan
  • Kitaodawara Hospital Meihoukai Medical Corporation Association
    Kanagawa, Japan
  • Shiunkai Yokohama Hospital
    Kanagawa, Japan
  • Soushu Hospital
    Kanagawa, Japan
  • Yatsushirokosei Hospital
    Kumamoto, Japan
  • Yuge Hospital
    Kumamoto, Japan
  • Sagaarashiyama Tanaka Clinic
    Kyoto, Japan
  • Miyagi Psychiatric Center
    Miyagi, Japan
  • Yasuda Hospital
    Miyagi, Japan
  • National Hospital Organization Komoro kogen Hospital
    Nagano, Japan
  • North Alps Medical Center Azumi Hospital
    Nagano, Japan
  • Syonan Hospital
    Nagano, Japan
  • Sanwa Central Hospital
    Nagasaki, Japan
  • Nara Medical University Hospital
    Nara, Japan
  • Akari Clinic
    Okinawa, Japan
  • Arakaki Hospital
    Okinawa, Japan
  • Samariya Hospital
    Okinawa, Japan
  • Keihan Hospital
    Osaka, Japan
  • Kyowakai Healthcare Corpration Hannan Hospital
    Osaka, Japan
  • Hoaki Hospital
    Ōita, Japan
  • Hizen Psychiatric Center
    Saga, Japan
  • Rainbow & Sea Hospital
    Saga, Japan
  • Sho Midori Hospital
    Saitama, Japan
  • Shiga University of Medical Science Hospital
    Shiga, Japan
  • Shimane University Hospital
    Shimane, Japan
  • Numazu Chuo Hospital
    Shizuoka, Japan
  • Abe Clinic
    Tokyo, Japan
  • Hozumi Clinic
    Tokyo, Japan
  • Kyorin University Hospital
    Tokyo, Japan
  • Maynds Tower Mental Clinic
    Tokyo, Japan
  • National Center of Neurology and Psychiatry
    Tokyo, Japan
  • Nishigahara Hospital
    Tokyo, Japan
  • Ongata Hospital
    Tokyo, Japan
  • Sangenjaya Neurology-Psychosomatic Clinic
    Tokyo, Japan
  • Senzoku Mental Clinic
    Tokyo, Japan
  • Kawada Hospital
    Toyama, Japan
  • Minamitoyama Nakagawa Hospital
    Toyama, Japan
  • Public Okitama General Hospital
    Yamagata, Japan
  • National Hospital Organization Kanmon Medical Center
    Yamaguchi, Japan
09

References and documents

Publications

  • Horiguchi J, Watanabe K, Kondo K, Iwatake A, Sakamoto H, Susuta Y, Masui H, Watanabe Y. Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: A multicenter, randomized, double-blind, placebo-controlled study (J-KINECT). Psychiatry Clin Neurosci. 2022 Nov;76(11):560-569. doi: 10.1111/pcn.13455. Epub 2022 Sep 17. PubMed 36114799 ↗
  • Watanabe Y, Susuta Y, Nagano M, Masui H, Kanahara N. Efficacy and Safety of Valbenazine in Elderly and Nonelderly Japanese Patients With Tardive Dyskinesia: A Post Hoc Analysis of the J-KINECT Study. J Clin Psychopharmacol. 2024 Nov-Dec;44(6):551-560. doi: 10.1097/JCP.0000000000001903. Epub 2024 Aug 27. PubMed 39186921 ↗
  • Nagano M, Susuta Y, Masui H, Watanabe Y, Watanabe K. Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study. J Clin Psychopharmacol. 2024 Mar-Apr 01;44(2):107-116. doi: 10.1097/JCP.0000000000001811. PubMed 38421921 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2017 to primary completion in Sep 2020, 39 months.

Results were first posted in Aug 2023, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2017
First posted
Jun 5, 2017
StartActual
Jun 21, 2017
Primary completionActual
Sep 29, 2020
CompletionActual
Sep 29, 2020
Results first posted
Aug 14, 2023
Last update
Jan 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03176771
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Jun 21, 2017
Primary completion
Sep 29, 2020
Completion
Sep 29, 2020
Results posted
Aug 14, 2023
Last update
Jan 7, 2026

Study contacts

General Manager
study director · Tanabe Pharma Corporation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion